Nasdaq:CLNN
Clene Inc.
A high-risk R&D intensive firm trading with minimal revenue but significant cash burn and negative equity positions.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock as a high-risk, high-reward speculative play on a potential technological breakthrough that could instantly monetize their vast R&D investments. The company's substantial paid-in capital provides a buffer against immediate liquidation, allowing management time to pivot strategies or secure new partnerships.
Bear Case
The fundamental financials show a company with negative equity and liabilities exceeding assets by nearly $10M, making it a prime candidate for bankruptcy or forced asset sales. With revenue under $1M annually and cash flow from operations draining reserves, there is no clear path to profitability visible in the current data.
About Clene Inc.
Clene Inc. is a technology company focused on advanced material science and manufacturing solutions, serving industrial sectors with proprietary chemical processing systems. The firm operates primarily in the materials and specialty chemicals market, leveraging research and development to develop specialized products for niche applications.
Analysis
Management Discussion
The company reported a net profit of -$39.4M for the latest period, continuing a trend of deep losses since 2022 despite slight fluctuations in annual revenue which remained negligible at $0.3M-$0.7M. While non-operating interest income provided some offsetting cash flow, the operational burn rate and shrinking cash reserves threaten long-term viability without significant external capital injection or a breakthrough in product sales.
Industry Overview
The specialty materials industry is characterized by high barriers to entry due to R&D costs and regulatory compliance, yet remains highly competitive with established players dominating market share. Companies in this space often face long development cycles where cash burn is high before any commercial revenue materializes.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $473.0K | $654.0K | $342.0K |
| Cost of Revenue | $26.0K | $121.0K | $70.0K |
| Gross Profit | $447.0K | $533.0K | $272.0K |
| Operating Expenses | $48.9M | $41.1M | $33.4M |
| Operating Income | $-48.4M | $-40.5M | $-33.1M |
| R&D | $31.9M | $26.7M | $20.1M |
| G&A | $16.9M | $14.4M | $13.3M |
| Stock-Based Comp | $8.5M | $9.1M | $8.0M |
| Depreciation | $1.0M | $1.7M | $1.6M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $18.5M | $-9.0M | $-6.3M |
| Interest Expense | — | $4.6M | — |
| Interest Income | — | $1.4M | $865.0K |
| Pre-Tax Income | $-29.9M | $-49.5M | $-39.4M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-29.9M | $-49.5M | $-39.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-29.9M | $-49.5M | $-39.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-29.9M | $-49.5M | $-39.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $29.2M | $38.9M | $16.2M |
| Cash & Equivalents | $18.3M | $28.8M | $12.2M |
| Marketable Securities | $5.0M | $6.2M | $0 |
| Accounts Receivable | $189.0K | $143.0K | $64.0K |
| Inventory | $43.0K | $37.0K | $68.0K |
| Prepaid Expenses | $5.6M | $3.7M | $3.9M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $15.3M | $13.5M | $11.2M |
| Operating Leases | $4.6M | $4.2M | $3.6M |
| Other LT Assets | $10.7M | $9.3M | $7.5M |
| Total Assets | $44.5M | $52.3M | $27.3M |
| Current Liabilities | $13.9M | $25.3M | $10.3M |
| Accounts Payable | $3.0M | $1.5M | $1.2M |
| Current Leases | $488.0K | $576.0K | $926.0K |
| Other Current Liab | $6.5M | $19.5M | $359.0K |
| Long-Term Liabilities | $27.4M | $13.6M | $25.9M |
| LT Operating Leases | $5.6M | $4.9M | $4.1M |
| Other LT Liab | $21.8M | $8.7M | $21.8M |
| Total Liabilities | $41.3M | $39.0M | $36.2M |
| Shareholders' Equity | $3.2M | $13.4M | $-8.9M |
| Paid-In Capital | $196.2M | $255.9M | $273.2M |
| Retained Earnings | $-193.2M | $-242.7M | $-282.1M |
| AOCI | $203.0K | $199.0K | $71.0K |
| Total L&E | $44.5M | $52.3M | $27.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-29.9M | $-49.5M | $-39.4M |
| Non-Cash Adjustments | $-10.7M | $23.6M | $14.6M |
| Working Capital Changes | $1.6M | $-4.2M | $3.5M |
| Cash from Operations | $-39.0M | $-30.2M | $-21.3M |
| Capital Expenditures | $5.2M | $330.0K | $15.0K |
| Cash from Investing | $-10.2M | $-1.5M | $6.3M |
| Cash from Financing | $17.2M | $42.2M | $-1.5M |
| FX Effect | $-30.0K | $-4.0K | $-127.0K |
| Net Change in Cash | $-32.0M | $10.5M | $-16.7M |
| Beginning Cash | $50.3M | $18.4M | $28.9M |
| Ending Cash | $18.4M | $28.9M | $12.2M |
Frequently Asked Questions
How does Clene Inc. make money?
Primary revenue streams include sales of specialized chemical intermediates, licensing of proprietary manufacturing processes, and potentially government or defense-related contracts given the nature of the technology. The financials suggest a heavy reliance on non-operating income (interest) to offset massive operating losses from R&D activities.
What are the main risks for CLNN?
Sustained net losses over the last three years with a massive retained earnings deficit of -$282.1M indicate severe financial distress and potential insolvency. Operating cash flow is highly negative at -$21.3M while total liabilities ($36.2M) exceed total assets ($27.3M), signaling a fragile balance sheet. Minimal revenue generation relative to R&D spend suggests an unproven commercialization model.
What is CLNN's competitive advantage?
Possesses significant intellectual property through its $20.1M annual research and development spend, creating potential moats in specialized material science niches. Maintains a large paid-in capital base of $273.2M which could be utilized for future strategic acquisitions or restructuring if profitability is achieved.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.